UPDATE ARTICLE

Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome

Authors

Maria Goretti Polito[1]

Gianna Mastroianni Kirstajn[2]

[1,2]Outpatients Clinics of Glomerulopathies of Universidade Federal de São Paulo – UNIFESP

Corresponding author:
Prof. Dra. Gianna Mastroianni Kirsztajn.
Universidade Federal de São Paulo, Escola Paulista de Medicina, Disciplina de Nefrologia, Setor de Glomerulopatias.
Rua Botucatu, 740. São Paulo – São Paulo – Brazil
CEP 04023-900
Tel: 55 (11) 5904-1699;
Fax: 55 (11) 5904-1684
E-mail: gianna@nefro.epm.br

We declare no conflict of interest.

ABSTRACT

Thrombotic microangiopathies (TMAs) are pathological conditions characterized by generalized microvascular occlusion by platelet thrombi, thrombocytopenia, and microangiopathic hemolytic anemia. Two typical phenotypes of TMAs are hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Other disorders occasionally present with similar manifestations. Depending on whether renal or brain lesions prevail, two pathologically indistinguishable but somehow clinically different disorders have been described: HUS and TTP. Injury to the endothelial cell is the central and likely inciting factor in the sequence of events leading to TMA. Loss of physiological thromboresistance, leukocyte adhesion to damaged endothelium, complement consumption, abnormal von Willebrand factor release and fragmentation, and increased vascular shear stress may then sustain and amplify the microangiopathic process. Intrinsic abnormalities of the complement system and of the von Willebrand factor pathway may account for a genetic predisposition to the disease that may play a paramount role in particular in familial and recurrent forms. In the case of diarrhea-associated HUS (D+HUS), renal endothelial damage is mediated (at least in large part) by the bacterial agent Shigatoxin (Stx), which is actually a family of toxins elaborated by certain strains of Escherichia coli and Shigella dysenteriae. Outcome is usually good in childhood, Shiga toxin-associated HUS, whereas renal and neurological sequelae are more frequently reported in adult, atypical, and familial forms of HUS and in TTP. Recent studies have demonstrated that deficiency in the von Willebrand factor cleaving protease ADAMTS13, due to deficiency of ADAMTS13 can be genetic or more common, acquired, resulting from autoimmune production of inhibitory anti-ADAMTS13 antibodies, that causes TTP. During the last decade, atypical HUS (aHUS) has been demonstrated to be a disorder of the complement alternative pathway dysregulation, as there is a growing list of mutations and polymorphisms in the genes encoding the complement regulatory proteins that alone or in combination may lead to aHUS. Approximately 60% of aHUS patients have so-called 'loss-of-function' mutations in the genes encoding the complement regulatory proteins, which normally protect host cells from complement activation: complement factor H (CFH), factor I (CFI) and membrane cofactor protein (MCP or CD46), or have 'gain-of-function' mutations in the genes encoding the complement factor B or C3. In addition, approximately 10% of aHUS patients have a functional CFH deficiency due to anti-CFH antibodies. Although TMAs are highly heterogeneous pathological conditions, one-third of TMA patients have severe deficiency of ADAMTS13. Platelet transfusions are contraindicated. Plasma infusion or exchange (PE) is the only treatment of proven efficacy.

Keywords: thrombotic microangiopathies, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, kidney failure, von Willebrand factor.

INTRODUCTION

Thrombotic microangiopathies (TMAs) are pathological conditions characterized by the presence of microangiopathic hemolytic anemia (due to shear stress in the microcirculation), generalized microvascular occlusion caused by platelet-rich thrombi (renal involvement is common), and thrombocytopenia (platelet consumption).[1] The two classical phenotypic manifestations of TMAs are thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS), serious conditions that put the patient's life at risk. Hemolytic-uremic syndrome is characterized by three already cited clinical signs (classical "triad"), while TTP is characterized by a set of five manifestations: the "triad" associated with fever and neurological signs. However, the two diseases cannot be clinically distinguished. Those TMAs should be differentiated from disseminated intravascular coagulation (DIC) and from consumptive thrombo-hemorrhagic disorders.[2] In fact, the spectrum of clinical manifestations of such disorders is very similar, the neurological abnormalities being commonly considered a characteristic of TTP, while acute kidney failure is a characteristic of HUS. Patients with those syndromes can have both, or none, abnormalities. This distinction has been valued to a certain extent because of the suggestion that treatment with plasma exchange (PE) would be appropriate to TTP, but not to HUS. Even considering that both are significantly clinically and histologically related, most recent investigations have shown that TTP and HUS have independent and non-related outcomes. Currently, investigations related to TTP have focused on the regulation of the blood coagulation protein, the von Willebrand factor (vWF), while studies on HUS have focused on understanding the mechanisms of renal endothelial injury.

It is worth emphasizing that the PE treatment is the combination of plasmapheresis (which can remove unusually large von Willebrand factor multimers and autoantibodies against ADAMTS13) and infusion of frozen fresh or cryosupernatant plasma (containing additional metalloprotease).[3,20]

DIAGNOSTIC CRITERIA FOR TMAs (TTP AND HUS)

According to previous studies,[2,4,5] TMAs have been defined as having all the following alterations: (1) microangiopathic hemolytic anemia (hemoglobin ≤ 12 g/dL), negative Coombs test, undetectable serum haptoglobin (< 10 mg/dL), more than two fragmented red blood cells (schizocytes) in a 100-x microscopic field (Figure 1), and an increase in lactic dehydrogenase (LDH) above the institutional baseline; (2) thrombocytopenia (platelet count ≤ 100x10⁹/L); and (3) organic dysfunction (renal and neurological involvement) of variable intensity with no signs of DIC.[6]

The differential diagnosis between HUS and TTP based on routine laboratory findings is usually very difficult.[7]

Approximately 90% of children with HUS have diarrhea [HUS associated with diarrhea (D+ HUS)] as a prodrome, usually with blood, caused by Shiga toxin (Stx), typically produced by *Escherichia coli* of the serotype O157:H7.[8] With support therapy, its mortality is 3%,[9] and, thus, treatment with PE is rarely necessary. Because that procedure is not used in children with HUS, the same diagnosis in adults can indicate that PE treatment is not necessary. Therefore, some authors avoid using the term HUS for adults, even in the presence of kidney failure. It is worth emphasizing that acute kidney failure manifests in 55% to 70% of the cases;[10-12] however, kidney function recovers in most cases (more than 70% in several case series).[12-15]

Leukocytosis can be extreme, in the form of a leukemoid reaction, being a positive predictor of acute mortality and residual nephropathy.[16-19] Children with diarrhea (D+ HUS) present a significantly higher leukocyte count than children with atypical HUS (D- HUS). This finding suggests that the intestinal disorder is an important factor implicated in the generation of leukocytosis.[17] In the Osaka outbreak in 1996, leukocyte count and C reactive protein (CRP) levels were higher in the group of children with diarrhea who developed HUS, when compared with infected children without that complication.[18]

Atypical HUS involves a heterogeneous group of patients not infected by the Stx-producing bacterium (5% of the HUS cases), which should be excluded as a cause of the disease. Atypical HUS can be sporadic or familial (that is, more than one family member affected by the disorder, once exposure to Stx-producing *E. coli* is excluded). The forms of D- HUS have a poor prognosis. More than 50% progress to chronic kidney failure or irreversible cerebral damage, and 25% evolve to death during the acute phase of the disease.[16] Recently, genetic studies have documented that the familial form is associated with genetic abnormalities of the complement regulatory protein, and there is evidence that similar genetic alterations can also predispose to sporadic cases of D- HUS.[21]

Unlike TTP, HUS is rarely induced by genetic mutations of complement regulation factors (factors B, H, and I, and CD46) and by auto-antibodies against factor H.[21]

In the era preceding its effective treatment, TTP was defined by the following "pentad" of clinical manifestations: thrombocytopenia; microangiopathic hemolytic anemia; neurological abnormalities; kidney failure; and sudden fever.[19] Efficacy of the treatment with PE requires immediate diagnosis and a reduction in the number of clinical criteria necessary for diagnosing the disease. The diagnostic criteria that have been used more recently include only thrombocytopenia and microangiopathic hemolytic anemia, with no apparent alternative etiology.[20] The use of fewer criteria is supported by the clinical findings at presentation of patients whose diagnosis of TTP had been confirmed by the presence of severe deficiency of ADMTS13: neurological and renal abnormalities were uncommon, fever was rare, and no patient had the complete "pentad" of clinical manifestations.[22] The feasibility of effective treatment and the reduction in number of the diagnostic criteria have resulted in an eight- to ten-fold increase in the number of patients treated with PE in cases of TTP.[23,24] Because the diagnosis of TTP requires that treatment to be considered,

Figure 1. Peripheral blood smear of a patient with TTP.

and because almost all adults who do not meet the diagnostic criteria for PTT can benefit from PE, some authors use the term TTP for almost all adults.

It is worth noting that, although a certain degree of kidney impairment with proteinuria and/or hematuria is common, arterial hypertension and acute kidney failure requiring dialysis are rare in TTP.[25]

The distinction between TTP and HUS[26] is extremely important, because of the cases of atypical HUS, since D+ HUS affects mainly children, who typically have diarrhea before the episode of kidney failure.[8,27] It is worth emphasizing the recent evidence that

neither the deficiency of ADAMTS13, nor the deficiency of complement regulators are sufficient for the development of TTP or atypical HUS, respectively.[25,27]

Acute inflammation in the pathogenesis of HUS

Initially described in 1925 as a syndrome comprising kidney failure, hemolytic anemia, and thrombocytopenia, HUS is usually considered a kidney disease with systemic complications.[1] While in TTP, the focus is on von Willebrand factor and ADAMTS13, in HUS, the focus is on the mechanism of renal endothelium injury mediated by Stx (at least, mostly), a family of toxins produced by certain strains of *Escherichia coli* and *Shigella dysenteriae*.[29,28]

Unlike TTP, patients with D+ HUS have plenty of evidence of an acute inflammatory response, whose magnitude predicts clinical outcome. There is evidence that inflammatory cells and their byproducts play a major role in: (1) loss of the intestinal barrier function, promoting the movement of endotoxin and Stx into the circulation; (2) delivery of Stx to target organs; (3) sensitization of target organs to Stx by increasing the intracellular glycolipid receptor expression; and (4) direct injury of target organ endothelium.[29]

The gastrointestinal disorder in patients with Stx-producing *E. coli* varies from an aqueous diarrhea to a severe form of hemorrhagic colitis. Colonic inflammation could play a role in the local intestinal microangiopathy, in the Stx transportation from the intestinal lumen through lamina propria into the circulation, and in the generation of severe systemic inflammatory response.[29,30] Recent evidence shows that Stx induces marked chemotactic response of human intestinal epithelial cells.[31] By using a colonic epithelial cell line, Stx led to superinduction of interleukin-8 (IL-8) with increase in both IL-8 protein and mRNA, despite the known inhibitory effects of Stx on protein elongation. Secretion of IL-8 into the lamina propria might create a chemokine gradient sufficient to recruit polymorphonuclear leukocytes (PMNs). Both IL-8 and tumoral necrosis factor alpha (TNF-alpha) are very elevated in stools of patients infected with Stx-producing *S. flexneri*.[32] Several potential consequences of the inflammatory response in lamina propria exist. Transepithelial migration of PMNs can lead to transient loss of colonic barrier function and cause the passage of luminal contents into circulation.[32-34] A recent study has shown the movement of PMNs from the basolateral membrane to the apical side of intestinal epithelial cells and the increase in translocation of both Stx1 and Stx2 in the opposite direction.[34] Loss

of barrier function could contribute to direct entry of Stx into the circulation, and endotoxemia could promote a systemic cytokine response. Increasing evidence, both *in vitro* and *in vivo*, suggests that Stx binds to PMNs, which is the trigger for their activation, and promotes adherence of PMNs to the target endothelium. Recently, Te Loo *et al.*[35] have found that Stx binds to PMNs (not via Gb3) and that these cells are direct carriers of the toxin from the intestine to target organs.[36] Shiga toxin circulates in the body, but can be preferentially located in the kidney, as a result from the high concentration of its receptor, globotriaosylceramide (Gb3), in the endothelium.

The D+ HUS (Table 1) is caused by Stx1 and Stx2, a component of the subunit A of 33 kDa and five subunits B of 7 kDa each, produced by *Escherichia coli* O157: H7.[37] In the circulation, it binds to the Gb3 receptor, which is widely expressed on glomerular endothelial cells. After receptor-mediated endocytosis, the subunit A of Stx is internalized and activated, leading to the depuration of specific adenosines in 28S ribosomal RNA, resulting in irreversible inhibition of protein elongation [38] and apoptosis of endothelial cells. This releases significant levels of Willebrand factor multimers (UL-VWFMS) into the circulation, resulting in platelet thrombi in the microcirculation. Glomerular endothelial cells and renal tubular epithelial cells express the Gb3 receptor, contributing to the development of kidney failure in infected patients. Thus, *E. coli* O157:H7 associated with TMAs seems to be induced independently from the plasma levels of ADAMTS13:AC[7] (normal activity of the vWF-cleaving protease), and efficacy of the treatment with PE is much less evident in such case.

By definition, the kidney is the target organ in HUS caused by Stx-producing *E. coli*. That vulnerability is mostly due to the high density of Gb3 receptors in renal tubular epithelial and microvascular endothelial cells.[39] In fact, renal tubular epithelial cells are maybe the major source of Gb3, in a quantity equal to or possibly greater than that of Vero cells. The pending question is how much of that vulnerability is due to the cytotoxic environment. The studies by Hughes *et al.*[40] and King *et al.*[43] have shown that those cells are extremely sensitive to the ribotoxic effects of Stx. Those studies have increased the possibility that acute tubular necrosis plays a role in kidney failure. Human glomerular microvascular endothelial cells express less Gb3 and are less sensitive to the ribotoxic effects of Stx. Even if the subsequent events are less well known, it is clear that the thrombotic state induced by Stx in HUS involves more than direct toxic

effect. Pretreatment of the glomerular microvascular endothelial cells with TNF-alpha substantially increased the density of the receptors and their sensitivity to Stx.[41] Those data suggest that inflammatory cytokines contribute to glomerular injury, because of an increase in Gb3 expression on glomerular microvascular endothelial cells, thus increasing the sensitivity of those cells to the ribotoxic effects of Stx and their vulnerability to undergo apoptosis. If the finding that Stx increases the expression of adhesion molecules is true for glomerular microvascular endothelial cells, such mechanism could serve as an accelerator of the glomerular injury due to an increase in Stx delivery.

Approximately 50% of the patients with atypical HUS (Table 2) carry a heterogeneous mutation in one of the four genes that encode the complement factors H (CFH), I (CFI), B (CFB), membrane cofactor protein (MCP) or CD46.[45-43] Those proteins control the complement activation on cell surface and limit cell injury mediated by complement in the host tissue. However, because of only partially known reasons, the glomerular endothelium is especially sensitive to loss of complement regulation, and the microvascular damage in atypical HUS is mainly limited to the renal circulation.

Since 1974, reduced serum levels of complement component C3 and normal serum levels of C4 have been shown in patients with atypical HUS (Table 2).[44-47] Patients with HUS and low levels of C3 have high activated complement (C) component levels, including C3b, C3c, and C3d. Granular deposits of C3 in glomeruli and arterioles during acute disease are consistent with complement activation and local C3 consumption.[48] Positive staining for C9 in glomeruli and small arteries with intimal proliferation and thrombosis indicates activation through the final lytic pathway (membrane attack complex C5b-9).

It is worth noting that the complement system consists of several plasma proteins and membrane-bound proteins that protect against the invasion of microorganisms.[47] There are three activation pathways (classical, lectin, and alternate), which produce proteases denominated C3 and C5 convertases, which cleave C3 and C5, respectively, and bind to the membrane attack complex. Hydrolysis of C3 in the plasma initiates the alternate pathway, leading to C3b deposition on almost all surfaces exposed to plasma. [47] In host cells, complement activation is controlled by both receptors, fluid-phase and membrane-anchored receptors, favoring C3b cleavage to inactive C3b (iC3d) by CFI (cofactor activity) and dissociating the multicomponents of C3 and C5-convertases (decay

Table 1	CLASSIFICATION AND TREATMENT OF THE DIFFERENT FORMS OF HUS	
Disease	**Causes**	**Treatment**
D+ HUS	Stx-producing Escherichia coli	Support
	Shigella dysenteriae type 1	Support and antibiotics
Non-Stx HUS (sporadic)	Bacterium (Streptococcus pneumoniae)	Antibiotics and plasma
	Virus (HIV)	Plasma
	Drugs (antineoplastic, antiplatelet, immunosuppressive drugs)	Drug interruption and plasma
	Pregnancy	Delivery, plasma
	Post-partum	Plasma
	Systemic diseases	
	Lupus	Steroids and plasma
	Scleroderma	Blood pressure control
	Antiphospholipid syndrome	Oral anticoagulant agents
	Idiopathic	Plasma
	Genetic (CFH, MCP, CFI)	Plasma
Familial	Genetic (CFH, MCP, CFI), plasma	Plasma

accelerating activity). Without normal regulation, C3b deposits increase more than 20 times[47] through the amplification loop and activate the complement cascade, which remains as such until the complement components are consumed. Injured cells that have no membrane-bound regulators or that cannot bind to soluble regulators are attacked by the complement. On the bacterial surface, C3b binds to specific receptors in neutrophils and macrophages, resulting in phagocytosis of the complement-labeled bacterium.

Complement component C3b also participates in the formation of C5-convertase and initiates the attack complex that causes cell lysis. That thin regulation is based on a certain number of membrane regulators (CR1, DAF, MCP, and Cd59) and fluid-phase regulators (Factor H) that protect the host cells.

This results in the formation of the membrane attack complex and recruitment of inflammatory cells, events that cause injury and retraction of endothelial cells, platelet adhesion and aggregation, an increase in

Table 2	GENETIC ABNORMALITIES AND CLINICAL EVOLUTION OF PATIENTS WITH ATYPICAL HUS					
Gene	**Major effect**	**Principal efeito**	**Frequency (%)**	**Short-term response with plasma therapy**	**Long-term evolution**	**Outcome of kidney transplant**
CFH	Factor H	Does not bind to endothelium	20-30	Remission rate: 60% (dose- and time-dependent)	Death rate or CKF: 70%-80%	Recurrence rate: 80%-90%
CFHR1/3	HR1/R3 factor	Antibody anti-CFH	6	Remission rate: 70%-80% (PE and immunosuppressive agents)	CKF rate: 30%-40%	Recurrence rate: 20%
MCP	MCP	Lack of surface expression	10-15	Non definitive indication for therapy	Death rate or CKF: <20%	Recurrence rate: 15%-20%
CFI	Factor I	Low cofactor level or activity	4-10	Remission rate: 30%-40%	Death rate or CKF: 60%-70%	Recurrence rate: 70%-90%
CFB	Factor B	Stabilization of C3b convertase	1-2	Remission rate: 30%	Death rate and CKF: 79%	Remission in one case
C3	C3	Resistance to C3b inactivation	5-10	Remission rate: 40%-50%	Death rate and CKF: 60%	Recurrence rate: 40%-50%
TM	TM	Reduction in C3b inactivation	5	Remission rate: 60%	Death rate and CKF: 60%	Remission in one case

the tissue factor with binding and activation of Factor VII, and formation of thrombin and fibrin polymers. That scenario applies particularly to the glomerular capillary bed, which is a fenestrated endothelium, whose surface of the basal membrane is rich in polyanions prone to Factor H1 binding, which could explain the localization of the HUS vascular injury.[49,50]

Membrane cofactor protein is also widely expressed in the kidneys and could be found in glomerular endothelial cells by use of immunohistochemistry analysis.[48-51] It plays an important role in the protection of glomerular endothelial cells against C3 activation, because the cofactor activity in the extract of those cells was completely blocked by antibodies anti-MCP.[51] Complement factor H and MCP act in conjunction to control the complement activation in host cells. Mutation in CFH and in MCP results in complement activation and HUS, indicating that the functions of those complement regulators do not overlap, being both required for complement control and activation.

The lesion of D+ HUS cannot be distinguished from that of the atypical form based on histological analysis. It is characterized by thickening of the capillaries and arterioles, endothelial edema and detaching, and accumulation of proteins and cell debris in the subendothelial space. Platelet thrombi occlude the capillary lumen. Hemolysis occurs and distorted and fragmented erythrocytes are evident on peripheral blood smears. The lesions typically affect the kidneys (mainly glomeruli and arterioles), but other organs can be involved, such as brain, heart, lungs, gastrointestinal tract, and pancreas.

Thrombotic Thrombocytopenic Purpura (TTP)

Immediate recognition of TTP is important, because the disease responds well to treatment with PE,[20] but TTP is associated with a high mortality rate when not treated. In the era preceding the effective treatment with PE, 90% of the patients with TTP died from systemic microvascular thrombosis that caused myocardial and cerebral infarction and kidney failure.[19] However, recognizing TTP may be difficult because of the variety of presentations and lack of specific criteria. The only consistent abnormalities are microangiopathic hemolytic anemia, characterized by fragmentation of red blood cells, and thrombocytopenia,[7] manifestations that can also occur in other conditions.

Prior to effective therapy, the diagnosis of TTP was based on the progressive appearance of the "pentad" of clinical manifestations: microangiopathic

hemolytic anemia, thrombocytopenia, renal and neurological abnormalities, and fever. However, the recognition of the efficacy of the therapy with PE resulted in the adoption of more comprehensive diagnostic criteria so that treatment could be initiated faster. A randomized study has shown the efficacy of the therapy with PE only for microangiopathic hemolytic anemia and thrombocytopenia with no apparent alternative cause; the frequency of neurological and renal abnormalities and fever was smaller than that in previous studies.[20] Thrombotic thrombocytopenic purpura occurs primarily in adults. Children with microangiopathic hemolytic anemia, thrombocytopenia, and kidney failure are considered to have HUS.[52,53] That is typically preceded by abdominal pain and diarrhea, and has been recognized since 1983 as a complication of infection caused by the Stx-producing bacterium, *E. coli* O157: H7. Currently, 91% of the children with typical HUS survive with support care, without PE treatment.

Those observations have suggested that TTP and HUS are two distinct syndromes,[1] an interpretation supported by studies that found a severe deficiency (< 5% of activity) in the vWF-cleaving protease, the ADAMTS13, in patients diagnosed with TTP, but not in patients with HUS. ADAMTS13 cleaves the large vWF multimers, which are synthesized and secreted by endothelial cells. When ADAMTS13 is not present, the result is an abnormal formation of large vWF multimers in the plasma and an increased ability to react with platelets and cause disseminated platelet thrombi, characteristic of TTP.[1]

However, n fact TTP and HUS are not distinct syndromes, since their essential diagnostic criteria – microangiopathic hemolytic anemia and thrombocytopenia – are the same. Neurological abnormalities are commonly considered as characteristic of TTP, and kidney failure as characteristic of HUS. Sometimes, patients with those syndromes have none of those abnormalities or have both.[59] In addition, the name of the syndrome – TTP or HUS – has acquired clinical importance, due to the suggestion that treatment with PE can be appropriate to TTP, but not to HUS.[53] Thus, the term "TTP" is used to describe microangiopathic hemolytic anemia and thrombocytopenia occurring in adults, with no apparent alternative cause, and with or without associated abnormalities, conditions or causes.

Thrombotic thrombocytopenic purpura is rare in children; in adults, it affects mainly women, black individuals, and obeses.[31]

The role of measuring the activity of ADAMTS13 and inhibitors remains uncertain.[31]

The vWF multimers are produced inside megakaryocytes and endothelial cells and stored in granules inside the platelets and in the Weibel-Palade bodies of endothelial cells. When compared to plasma ones, such large multimers bind more efficiently to the glycoprotein Ibα component of the platelet glycoprotein Ib/IX/V receptor for vWF. This may be due to the fact that the binding site for the Ibα glycoprotein in the vWF monomeric subunit is more exposed in large multimers than in small ones, which are usually circulating. The initial attack of a small amount of large vWF multimers against Ibα glycoprotein, and subsequent formation of the IIb/IIIa glycoprotein complex of activated platelet by ADP, induces *in vitro* platelet aggregation in the presence of increased shear stress.[22,54]

Plasma vWF metalloproteinase usually prevents the entry of large vWF multimers in the circulation (or persistence). That enzyme breaks down the multimers by cleaving the peptide bindings in the vWF monomeric subunit in position 842–843 (between tyrosine and methionine). The metalloproteinase is called ADAMTS13 (disintegrin and metalloproteinase with thrombospondin-1-like domain), a member of the family of the calcium and zinc-dependent proteases. ADAMTS13 has a sequence arginine-glycine-aspartate, is mainly produced in hepatocytes, and its gene is located in chromosome 9q34.[55]

The large vWF multimers are probably cleaved by ADAMTS13 directly on the surface of endothelial cells. The thrombospondin-1-like domain of ADAMTS13 can bind to the enzyme in the thrombospondin receptor on the surface of endothelial cells.[56]

Severe deficiency of ADAMTS13 can be caused by genetic mutations (ADAMTS13: AC) or by autoantibodies (ADAMTS13: INH) acquired against that enzyme. In 1994, Tandon *et al.*[57] reported that approximately 80% of the patients with acquired TTP had autoantibodies against CD36. In 2009, Davis *et al.*[58] showed that ADAMTS13 binds especially to CD36 *in vitro*. CD36 is expressed in endothelial cells, platelets, and monocytes, and binds to thrombospondin 1. It has not been clarified whether the autoantibodies block the ADAMTS13 binding to endothelial cells, but this is the only way of interfering with efficient cleavage of vWF by ADAMTS13, resulting in TTP.

DISEASES THAT CAN MIMIC THE CLINICAL FINDINGS OF TTP

Because the diagnostic criteria of TTP are not specific, multiple systemic diseases can mimic TTP, resulting in misdiagnosis. The systemic diseases include disseminated malignant neoplasias,[59,60] systemic infections,[61-63] malignant hypertension,[64,69] systemic lupus erythematosus, and other kidney diseases.[69] In addition, physicians should maintain continued vigilance regarding the existence of possible alternative diseases, even after establishing the diagnosis of TTP, and starting treatment with PE.

TREATMENT OF D+ HUS

Correction with isotonic saline or ringer lactate to prevent oliguria on the first four days, as well as the correction of electrolytic abnormalities by use of dialysis seem to play a relevant role in survival in cases of D+ HUS in the short run.[65] The use of analgesics, anti-inflammatory and antimotility agents should be avoided; morphine and acetaminophen have good effects. Approximately 80% of the patients need blood transfusion because of symptomatic anemia. Platelet transfusion is indicated for important hemorrhages or procedures.

The use of antibiotics that interact with bacterial DNA, such as gyrase inhibitors (fluoroquinolones), alkylating agents (mytomicin C, TMP/SMX), and β-lactam antibiotics induce lysogenesis of the bacteriophage, with an increase in Stx expression. Ikeda *et al.*[66] have shown that fosfomycin administered on the second day of diarrhea protects against the development of HUS caused by *E. coli* O157:H7.

Oral administration of the first generation of the Gb3 analogue - Synsorb-Pk[67] - when initiated after the diagnosis of HUS failed to improve the course of the disease in a randomized study.

TREATMENT FOR ATYPICAL HUS

Despite the poor prognosis of atypical HUS, after the introduction of the therapy with plasma, the mortality rate dropped from 50% to 25%.[13,68-70] However, the effectiveness of the use of plasma in the treatment of acute episodes is still controversial.[71] Some studies have shown that a consistent percentage of patients with atypical HUS respond to treatment with plasma. Plasma exchange has been proposed to be relatively more effective than plasma infusion, because it should remove potentially toxic substances from the circulation of patients.

Treatment with plasma should be initiated within 24 hours from presentation, since its delay can increase the frequency of therapeutic failure.[73]

Other treatments, such as antiplatelet agents, prostacyclins, heparin or fibrinolytic agents, steroids, and immunoglobulins, have been tested, and the results have been inconsistent.[13]

Diagnostic and prognostic role of measuring ADAMTS13

Measuring ADAMTS13 may not guarantee initial diagnosis and therapeutic decision, but it is important for the prognosis. Even if most patients with severe ADAMTS13 deficiency do not have kidney failure, measuring its activity can distinguish TTP from HUS.[74] Some patients with severe ADAMTS13 deficiency can have acute kidney failure. An ADAMTS13 activity < 5% seems to be specific for TTP, but it does not identify all patients who can relapse; ADAMTS13 activity < 10% essentially identifies all patients at risk for relapsing, but it is not specific for that purpose; patients with sepsis[75,76] and liver cirrhosis[77] can also have ADAMTS13 activity < 10%.

Treatment with "plasma exchange"

Plasma exchange is the essential treatment for all patients diagnosed as having TTP, with or without kidney failure,[20,78] but the number of PE sessions required for remission is extremely variable. Before effective treatment, most survivors were children,[19] which can reflect their inherent resistance to thrombosis, as suggested by observations that venous and arterial thromboses are rare in children.[79]

The hypothesis that tries to explain the efficacy of PE treatment considers that ADAMTS13 deficiency is corrected by the infusion of plasma and inhibitor; autoantibodies are removed by use of apheresis, resulting in recovery of ADAMTS13 activity.[1] However, most adult patients diagnosed with TTP do not have severe ADAMTS13 deficiency, and many seem to also respond to PE, like those presenting with bloody diarrhea or who have TTP induced by quinine.[80-81] The mechanism of the possible efficiency of the PE treatment in those patients is unknown.

Even if several cases have suggested that plasma cryosupernatant, which is deficient in vWF, can be better than fresh plasma as a reposition product in PE, a small randomized clinical trial failed in the attempt to confirm that finding.[81]

Based on those observations, PE should be performed every day and maintained until platelet count returns to normal.[31,82] Levels of LDH, which reflect tissue ischemia and hemolysis,[83] are also markers of response to treatment.[29]

Complications of the treatment with "plasma exchange"

When deciding about initiating PE treatment, the potential complications and confidence in TTP diagnosis should be taken into account. Of 206 consecutive patients assessed over a period of nine years in the registry of Oklahoma, 57 (28%) had complications and the death of five (2.4%) was attributed to that therapeutic approach. [84-86] The deaths were caused by hemorrhage or pneumothorax, complicating the insertion of central venous catheter (two patients), or sepsis attributed to central venous catheter (three patients). Two other patients had cardiac arrest with pulse electrical activity: one caused by anaphylactic reaction to plasma and the other caused by cardiac tamponade related to catheter insertion.

Adjuvant treatment

There is evidence that the PE treatment would have only a transient effect on the presumably autoimmune basis of the disease, and that additional immunosuppressive treatment could lead to a longer-lasting response.[31]

Treatment with immunosuppressive agents is reserved for patients suspected of having ADAMTS13 autoimmune deficiency. Corticoids are the immunosuppressive agents initially administered. Others agents, such as rituximab[87] and cyclosporine,[88] are used for more critically-ill patients. Aspirin is not used as adjuvant treatment, but is appropriate for patients with standard cardiologic or neurological indication and without severe thrombocytopenia.

Mortality

Despite the institution of treatment considered optimal, mortality among patients with TTP remains approximately 15%. However, 50% of the deaths can be attributed to complications from the treatment with PE or hospitalization, such as sepsis, hemorrhage, and thrombosis.[89]

Treatment of the patients who achieved remission

In patients with severe ADAMTS13 deficiency, the risk of relapse is approximately 40%, but it is rare in patients with less severe deficiency; 50% of these patients can relapse, most within one year.[89] The value of maintaining the immunosuppressive treatment or of measuring ADAMTS13 activity during remission is unknown. Patients can have severe ADAMTS13 deficiency for many years with no clinical evidence of TTP. In continuing with treatment, it is paramount to to insist with the patient to immediately have a platelet count, when any acute symptom occurs.

Because many young women develop TTP associated with pregnancy,[90,91] the risk of relapse with a future pregnancy becomes a concern. Follow-up study of 30 pregnancies in 19 women who had TTP revealed that most subsequent pregnancies were not affected.[91]

Long-term outcome

Even if relapse is a major problem, it is not the only one. After recognizing the disease, patients have a significantly altered quality of life, with progressive memory loss and fatigue.[92]

Acknowledgements

References

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600.
2. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927-35.
3. Moake JL. Haemolytic-uraemic syndrome: basic science. Lancet 1994; 343:393-7.
4. Ho VT, Cutler C, Carter S et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:571-5.
5. Ruutu T, Barosi G, Benjamin RJ et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92:95-100.
6. Wada H, Wakita Y, Nakase T et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 51:255-60.
7. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008. Inter Med 2010; 49:7-15.
8. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073-86.
9. Karpac CA, Li X, Terrell DR et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008; 141:696-707.
10. Tonshoff B, Sammet A, Sanden I et al. Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron 1994; 68:63-70.
11. Banatvala N, Griffin PM, Greene KD et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic finding. J Infect Dis 2001; 183:1063-70.
12. Milford D. The hemolytic uremic syndromes in the United Kingdom. In: Hemolytic Uremic and Thrombotic Thrombocytopenic Purpura, edited by Kaplan BS, Trompeter RS, Moake JL. New York, Marcel Dekker, 1992, pp. 39-59.
13. Ruggenenti P, Noris M, Remuzzi. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831-6.
14. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9:1126-33.
15. van Dyck M, Proesmans W, Depraetere M. Hemolytic uremic syndrome in childhood: renal function ten years later. Clin Nephrol 1988; 29:109-12.
16. Shieppati A, Ruggenenti P, Cornejo RP et al. Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. J Am Soc Nephrol 1992; 2:1640-4.
17. Walters MD, Matthel U, Jay R et al. The polymorphonuclear count in childhood hemolytic uremic syndrome. Pediatr Nephrol 1989; 3:130-4.
18. Ikeda K, Ida O, Kimoto K et al. Predictors for the development of haemolytic uraemic syndrome with Escherichia coli O157:H7 infections: With focus on the day of illness. Epidemiol Infect 2000; 124:343-9.
19. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45:139-59.
20. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325:393-7.
21. Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets 2009; 9:36-50.
22. Vesely SK, George JN, Lämmle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 101:60-8.
23. Clark WF, Garg AX, Blake PG et al. Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 2003; 290:1351-5.
24. George JN, Kremer Hovinga JA, Terrell DR et al. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Registry: the Swiss connection. Eur J Haematol 2008; 80:277-86.
25. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006; 70:16-23.
26. Ray PE, Liu XH. Pathogenesis of Shiga toxin induced hemolytic uremic syndrome. Pediatr Nephrol 2001;16:823-39.
27. Kavanagh D, Goodship TH, Richards A. Atypical haemolytic uraemic syndrome. Br Med Bull 2006; 77-78:5-22.
28. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035-50.
29. King AJ. Acute inflammation in the pathogenesis of hemolytic-uremic syndrome. Kidney Int 2002; 61:1553-64.
30. Allford SL, Hunt BJ, Rose P et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120:556-73.
31. Thorpe CM, Hurley BP, Lincicome LL et al. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect Immunol 1999; 67:5985-93.
32. Raqib R, Wretlind B, Anderson J et al. Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. J Infect Dis 1995; 171:376-84.

33. Nash S, Stafford J, Madara JL. Effects of polymorpho-nuclear leukocyte transmigration on the barrier function of the cultured intestinal epithelial monolayers. J Clin Invest 1987; 80:1104-13.

34. Hurley BP, Thorpe C, Acheson DWK. Neutrophil translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69:6148-55.

35. Te Loo DM, Monnens LA, van Der Velden TJ et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95:3396-402.

36. Newburg DS, Chaturvedi P, Lopez EL et al. Susceptibility of hemolytic-uremic syndrome relates to erythrocyte glycosphingolipid patterns. J Infect Dis 1993; 168:476-9.

37. Siegler RL, Pavia AT, Christofferson RD et al. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994; 94:35-40.

38. Endo Y, Tsurugi K, Yutsudo T. Site of action of a Verotoxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. Eur J Biochem 1988; 171:45-50.

39. Obrig TG, Louise CB, Lingwood CA et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993; 268:15484-8.

40. Hughes AK, Stricklett PK, Kohan DE. Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. Kidney Int 1998; 54:1093-106.

41. Van Setten PA, van Hinsbergh VWM, van der Velden TJAN et al. Effects of TNF[alfa] on verocytotoxin in purified human glomerular microvascular endothelial cells. Kidney Int 1997; 51:1245-56.

42. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007; 104:240-5.

43. Noris M, Ruggenenti P, Perna A et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999; 10:281-93.

44. Stuhlinger W, Kourilsky O, Kanfer A et al. Haemolytic-uraemic syndrome: Evidence for intravascular C3 activation [Letter]. Lancet 1974; 2:788-9.

45. Carreras L, Romero R, Requesens C et al. Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype. JAMA 1981; 245:602-4.

46. Hammar SP, Bloomer HA, McCloskey D. Adult hemolytic uremic syndrome with renal arteriolar deposition of IgM and C3. Am J Clin Pathol 1978; 70:434-9.

47. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140-4.

48. Devaux P, Christiansen D, Fontaine M et al. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur J Immunol 1999; 29:815-22.

49. Endoh M, Yamashina M, Ohi H et al. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin Exp Immunol 1993; 94:182-8.

50. Ichida S, Yuzawa Y, Okada H et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994; 46:89-96.

51. Nakanishi I, Moutabarrik A, Hara T et al. Identification and characterization of membrane cofactor protein (CD46) in the human kidneys. Eur J Immunol 1994; 24:1529-35.

52. Brain MC, Dacie JV, Hourihane DO. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Br J Haematol 1962; 8:358-74.

53. Gasser C, Gautier E, Steck A et al. Hämolytisch-urämische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955; 85:905-9 (Abstract).

54. Moake JL, Rudy CK, Troll JH et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307:1432-5.

55. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413:488-94.

56. Dong J, Nolasco LH, Arceneaux W et al. Endothelial von Willebrand factor multimers form extremely long strings that are efficiently cleaved by constituents of normal plasma but not of plasma from patients with thrombotic thrombocytopenic purpura. Blood 2001; 98:752a.

57. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 88:816-25.

58. Davis AK, Makar RS, Stowell CP et al. ADAMTS 13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009; 49:206-13.

59. Francis KK, Kojouri K, George JN. Occult systemic carcinoma masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Community Oncol 2005; 2:339-43.

60. Francis KK, Kalyanam N, Terrell DR et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 cases and a systematic review of the literature. Oncologist 2007; 12:11-9.

61. Robboy SJ, Salisbury K, Ragsdale B et al. Mechanism of Aspergillus-induced microangiopathic hemolytic anemia. Arch Intern Med 1971; 128:790-3.

62. George JN, Vesely SK, Terrell DR. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41:60-7.

63. Selleng K, Warkentin TE, Greinacher A et al. Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected with Staphylococcus epidermidis: role of monocyte procoagulant activity induced by bacterial supernatant. Amer J Hematol 2006; 82:766-71.

64. Egan JA, Bandarenko N, Hay SN et al. Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenic purpura. J Clin Apheresis 2004; 19:125-9.

65. Bitzan M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int 2009; 75:S62-S66.

66. Ikeda K, Ida O, Kimoto K *et al*. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying *Escherichia coli* O157:H7 infection. Clin Nephrol 1999; 52:357-62.

67. Trachtman H, Cnaan A, Christen E *et al*. Effect of an oral Shiga toxin binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337-44.

68. Hollenbeck M, Kutkuhn B, Aul C *et al*. Haemolytic-uraemic syndrome and thrombotic-thrombocytopenic purpura in adults: Clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant 1998; 13:76-81.

69. Lara PN Jr, Coe TL, Zhou H *et al*. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 1999; 107:573-9.

70. Morel-Maroger L, Kanfer A, Solez K *et al*. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): Clinicopathologic study in 20 adults. Kidney Int 1979; 15:548-58.

71. Clark WF, Rock GA, Buskard N *et al*. Therapeutic plasma exchange: An update from the Canadian Apheresis Group. Ann Intern Med 1999; 131:453-62.

72. Tostivint I, Mougenot B, Flahault A *et al*. Adult haemolytic and uraemic syndrome: Causes and prognostic factors in the last decade. Nephrol Dial Transplant 2002; 17:1228-34.

73. Ruggenenti P, Galbusera M, Cornejo RP *et al*. Thrombotic thrombocytopenic purpura: Evidence that infusion rather than removal of plasma induces remission of the disease. Am J Kidney Dis 1993; 21:314-8.

74. Furlan M, Robles R, Galbusera M *et al*. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-84.

75. Ono T, Mimuro J, Madoiwa S *et al*. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107:528-34.

76. Nguyen TC, Liu A, Liu L *et al*. Acquired ADAMTS13 deficiency in pediatric patients with severe sepsis. Haematologia 2007; 92:121-4.

77. Uemura M, Fujimura Y, Matsumoto M *et al*. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99:1019-29.

78. Rock GA, Shumak K, Kelton J *et al*. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992; 32:710-4.

79. Richardson MW, Allen GA, Monahan PE. Thrombosis in children: current perspective and distinct challenges. Thromb Haemost 2002; 88:900-11.

80. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Int Med 2001; 135:1047-51.

81. Rock G, Shumak KH, Sutton DMC *et al*. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94:383-6.

82. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96:1223-9.

83. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13:16-19.

84. Rizvi MA, Vesely SK, George JN *et al*. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2000; 40:896-901.

85. McMinn JR, Thomas IA, Terrell DR *et al*. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: an additional study of 78 consecutive patients. Transfusion 2003; 43:415-6.

86. Howard MA, Williams LA, Terrell DR *et al*. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. III. An additional study of 57 consecutive patients, 2002–2005. Transfusion 2006; 46:154-6.

87. George JN, Woodson RD, Kiss JE *et al*. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis 2006; 21:49-56.

88 Cataland SR, Jin M, Ferketich AK *et al*. An evaluation of cyclosporine and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 132:146-9.

89. George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989–2007. Kidney Int 2009; 112:S52-S54.

90. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003; 10:339-44.

91. Vesely SK, Li X, McMinn JR *et al*. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004; 44:1149-58.

92. Lewis QF, Scott JG, Kremer Hovinga JA *et al*. Neurocognitive impairment following recovery from ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood 2007; 110:395